Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

PoxviRus cOnTrolled EmergenCy using Therapeutics and Innovative VaccinEs

Project description

Preparedness for future mpox outbreaks

Once largely confined to Central and West Africa, mpox has spread globally through human-to-human transmission. The World Health Organization (WHO) declared the outbreak a public health emergency of international concern in August 2024, the second such declaration since 2022. The ERC-funded PROTECTIVE project aims to meet the need for better countermeasures. Specifically, it will isolate powerful monoclonal antibodies from infected or vaccinated individuals and use them to identify viral targets for next-generation vaccines. Generative AI will speed this process, helping design new immunogens and paving the way for faster, broader protection against mpox and future emerging pathogens.

Objective

Recent Monkeypox (mpox) outbreaks have caught once again the world unprepared. Low-middle income countries are currently most affected by mpox, however cases keep being reported worldwide. The continues circulation of mpox can rapidly burst in a global crisis that can set-back our world into chaos, reminiscing the recent pandemic. Lack of effective and affordable medical interventions urges the need to develop innovative countermeasures against orthopoxviruses. Recent technologies and methodological advancements allow to develop vaccines and monoclonal antibodies (mAbs) in record time, and their use can be vital to stop current and future orthopoxvirus-related threats. Here we propose to discover and develop mAbs against mpox and other orthopoxviruses. These reagents will be crucial to identify and design novel protective antigens to develop innovative vaccines. We will isolate, through an antigen-agnostic approach, mAbs from mpox infected or vaccinated individuals to build a panel of neutralizing mAbs (nAbs) able to recognize orthopoxviruses shared and protective epitopes. Generative artificial intelligence will be systemically integrated in our workflow to identify antigens targeted by discovered nAbs at unprecedented speed. Data-augmentation and iterative deep-learning models will be used to in silico design new vaccine immunogens which can be produced as recombinant proteins or mRNA, or loaded on nanoparticles. This approach will provide broadly nAbs and effective vaccines designed to protect from mpox and other orthopoxviruses. If successful, the approach herein proposed will fuel the field of vaccinology allowing unprecedent speed for antigen discovery and vaccine development. This approach could be translated to all pathogens for which no cure or prevention are available including emerging viral pathogens and antimicrobial resistant bacteria. This will strongly increase European competitiveness in fighting infectious disease and control future crisis.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

Fondazione Biotecnopolo di Siena
Net EU contribution
€ 1 499 375,00
Address
Strada del Petriccio e Belriguardo, 35
53100 Siena
Italy
Region
Centro (IT) Toscana Siena
Activity type
Other
Links
Total cost
€ 1 499 375,00

Beneficiaries (1)